Correlation Between Intellipharmaceutics and Scopus Biopharma
Can any of the company-specific risk be diversified away by investing in both Intellipharmaceutics and Scopus Biopharma at the same time? Although using a correlation coefficient on its own may not help to predict future stock returns, this module helps to understand the diversifiable risk of combining Intellipharmaceutics and Scopus Biopharma into the same portfolio, which is an essential part of the fundamental portfolio management process.
By analyzing existing cross correlation between Intellipharmaceutics International and Scopus Biopharma, you can compare the effects of market volatilities on Intellipharmaceutics and Scopus Biopharma and check how they will diversify away market risk if combined in the same portfolio for a given time horizon. You can also utilize pair trading strategies of matching a long position in Intellipharmaceutics with a short position of Scopus Biopharma. Check out your portfolio center. Please also check ongoing floating volatility patterns of Intellipharmaceutics and Scopus Biopharma.
Diversification Opportunities for Intellipharmaceutics and Scopus Biopharma
-0.21 | Correlation Coefficient |
Very good diversification
The 3 months correlation between Intellipharmaceutics and Scopus is -0.21. Overlapping area represents the amount of risk that can be diversified away by holding Intellipharmaceutics Internati and Scopus Biopharma in the same portfolio, assuming nothing else is changed. The correlation between historical prices or returns on Scopus Biopharma and Intellipharmaceutics is a relative statistical measure of the degree to which these equity instruments tend to move together. The correlation coefficient measures the extent to which returns on Intellipharmaceutics International are associated (or correlated) with Scopus Biopharma. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when the price movement of Scopus Biopharma has no effect on the direction of Intellipharmaceutics i.e., Intellipharmaceutics and Scopus Biopharma go up and down completely randomly.
Pair Corralation between Intellipharmaceutics and Scopus Biopharma
If you would invest 10.00 in Scopus Biopharma on September 5, 2024 and sell it today you would earn a total of 0.00 from holding Scopus Biopharma or generate 0.0% return on investment over 90 days.
| Time Period | 3 Months [change] |
| Direction | Moves Against |
| Strength | Insignificant |
| Accuracy | 100.0% |
| Values | Daily Returns |
Intellipharmaceutics Internati vs. Scopus Biopharma
Performance |
| Timeline |
| Intellipharmaceutics |
Risk-Adjusted Performance
0 of 100
Weak | Strong |
Very Weak
| Scopus Biopharma |
Risk-Adjusted Performance
0 of 100
Weak | Strong |
Very Weak
Intellipharmaceutics and Scopus Biopharma Volatility Contrast
Predicted Return Density |
| Returns |
Pair Trading with Intellipharmaceutics and Scopus Biopharma
The main advantage of trading using opposite Intellipharmaceutics and Scopus Biopharma positions is that it hedges away some unsystematic risk. Because of two separate transactions, even if Intellipharmaceutics position performs unexpectedly, Scopus Biopharma can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Scopus Biopharma will offset losses from the drop in Scopus Biopharma's long position.The idea behind Intellipharmaceutics International and Scopus Biopharma pairs trading is to make the combined position market-neutral, meaning the overall market's direction will not affect its win or loss (or potential downside or upside). This can be achieved by designing a pairs trade with two highly correlated stocks or equities that operate in a similar space or sector, making it possible to obtain profits through simple and relatively low-risk investment.| Scopus Biopharma vs. Scpharmaceuticals | Scopus Biopharma vs. DiaMedica Therapeutics | Scopus Biopharma vs. Monopar Therapeutics | Scopus Biopharma vs. Pasithea Therapeutics Corp |
Check out your portfolio center.Note that this page's information should be used as a complementary analysis to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Equity Search module to search for actively traded equities including funds and ETFs from over 30 global markets.
Other Complementary Tools
| CEOs Directory Screen CEOs from public companies around the world | |
| Portfolio Volatility Check portfolio volatility and analyze historical return density to properly model market risk | |
| Cryptocurrency Center Build and monitor diversified portfolio of extremely risky digital assets and cryptocurrency | |
| Equity Search Search for actively traded equities including funds and ETFs from over 30 global markets | |
| Portfolio Diagnostics Use generated alerts and portfolio events aggregator to diagnose current holdings |